Sweta Sharma Saha

Sweta Sharma Saha is a Vice Chancellor's Research Fellow at Teesside University's School of Health and Life Sciences, leading the Teesside Oncology Research Program (TORCH) focused on ovarian cancer. She holds a PhD in Cancer Biology from the National Institute of Biomedical Genomics, India, and has conducted postdoctoral research at the University of Chicago and Newcastle University. Her research emphasizes translational cancer therapeutics, DNA damage response pathways, and immune regulation. She leads a collaborative team at the National Horizons Centre and has secured grants totaling over £200,000 from organizations like Boehringer Ingelheim, Sarissa Inc, and Newcastle University. Notable awards include the Sigal Immuno-oncology Award and ProBio Africa Fellowship. Her work spans ovarian and breast cancers, with a focus on tumor heterogeneity, therapy resistance, and precision medicine approaches.

Education: PhD in Cancer Biology (2017, National Institute of Biomedical Genomics); MSc/Microbiology (2009, University of Calcutta); BSc/Microbiology (2007, University of Calcutta).

Research Interests: (1) Tumor immune microenvironment in ovarian cancer, (2) Cross-talk between DNA damage and immune response, (3) Novel therapeutic strategies for therapy-resistant cancers. Collaborations include projects with Merck KGaA, Sarissa Inc, and clinical partners at The James Cook University Hospital.

Grants & Projects: Current funding includes a £168,724 Boehringer Ingelheim grant exploring pan-KRAS inhibitors for ovarian cancer. Past projects include collaborations with Dr. Mark Vincent (London Regional Cancer Centre) on RAD51 inhibitors and studies on exercise-induced DNA repair modulation with Dr. Sam Orange.

Professional Activities: Member of Biochemical Society, Gynaecology Trials Group (UK), and multiple peer review bodies. Serves as academic lead for TORCH and chairs interdisciplinary cancer research initiatives.